Eli Lilly and Company (LLY)vsOwlet Inc (OWLT)
LLY
Eli Lilly and Company
$974.96
-1.22%
HEALTHCARE · Cap: $862.01B
OWLT
Owlet Inc
$4.86
-6.54%
HEALTHCARE · Cap: $142.34M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 68248% more annual revenue ($72.25B vs $105.71M). LLY leads profitability with a 35.0% profit margin vs -37.5%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
OWLT
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+30.6%
Fair Value
$15.80
Current Price
$4.86
$10.94 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.8% YoY
Revenue surging 29.6% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.9x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -802.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : OWLT
The strongest argument for OWLT centers on Revenue Growth. Revenue growth of 29.6% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : OWLT
The primary concerns for OWLT are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
OWLT carries more volatility with a beta of 1.83 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 32/100), backed by strong 35.0% margins and 55.5% revenue growth. OWLT offers better value entry with a 30.6% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Owlet Inc
HEALTHCARE · MEDICAL DEVICES · USA
Owlet Inc. is a leading innovator in infant health technology, focused on enhancing the safety and well-being of newborns through state-of-the-art monitoring solutions. The company's flagship product, the Owlet Smart Sock, employs advanced pulse oximetry to deliver real-time data on infants' heart rates and oxygen levels directly to parents’ mobile devices, empowering them with critical health insights. As the demand for pediatric health monitoring grows, Owlet is strategically positioned to broaden its product portfolio and solidify its standing in the dynamic infant health market. By emphasizing actionable data and improving pediatric care, Owlet is establishing a robust foothold at the intersection of healthcare and technology, appealing to institutional investors keen on innovative health solutions.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?